|
|
<p>2015年1月22日讯 /生物谷BIOON/ --默沙东近日宣布，已成功完成对抗生素巨头Cubist所有在外流通普通股每股102美元的要约收购。截止2015年1月20日，58039667股普通股已有效投标，约占Cubist在外流通股的75.7%。随着要约收购的圆满完成，默沙东预计在21日晚些时候通过全资子公司并入Cubist完成收购。合并完成后，Cubist将成为默沙东全资子公司，Cubist的普通股将停止在纳斯达克股市交易。</p><p>去年12月初，默沙东正式宣布与Cubist达成最终收购协议，以每股102美元溢价35%现金收购Cubist。该笔交易总价值高达95亿美元，包括84亿美元股权估值和11亿美元的净债务及其他考虑因素。该笔交易的关键产品Zerbaxa，在去年圣诞节前夕拿到了FDA批准，着实让默沙东高兴了一把。Zerbaxa（ceftolozane/他唑巴坦）也是Cubist在2014年拿下的第2个FDA批准。在欧盟监管方面，Zerbaxa预计将在2015年下半年获批。</p><p>目前，面对日趋严峻的“抗菌”形势，一些国家已经开始采取激励措施，鼓励新抗生素的研发。美国于2012年7月通过了《鼓励开发抗生素法案》(GAIN)，根据规定，符合标准的抗生素药物将获得额外五年的市场独占权，以帮助开发者收回投资。而Zebraxa就是根据《鼓励开发抗生素法案》(GAIN)批准治疗革兰氏阴性菌的首个新抗生素产品。</p><p>关于该笔交易，默沙东表示，Cubist是抗生素领域的全球领导者，过去20多年来一直致力于通过发现、开发和供应抗生素治疗严重潜在危及生命的感染，解决全球的公共卫生问题。目前，Cubist已建立了一个强大的管线资产，包括已上市产品及后期管线产品。将Cubist在全球抗生素领域的专长与默沙东雄厚的实力和全球影响力强强联合，将使默沙东在医院急诊护理领域创造一个更有利的地位，同时解决关键领域未获满足的医疗需求，如抗生素耐药性。</p><p>此外，收购Cubist与默沙东2013年推出的全球倡议和战略相互补，尤其是加强关键治疗领域的投资回报潜力，收购Cubist将直接使该公司2015年新增10亿美元收入。（生物谷Bioon.com）</p><p>英文原文：Merck Completes Tender Offer to Acquire Cubist</p><p>Wednesday, January 21, 2015 8:00 am EST</p><p>KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7 percent of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares.</p><p>Following consummation of the tender offer, Merck expects to complete the acquisition of Cubist later today through a merger of Merck’s wholly owned subsidiary with and into Cubist without stockholder approval. Upon completion of the merger, all outstanding shares of common stock of Cubist, other than shares held by Cubist in treasury or shares held by Cubist’s stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $102.00 offer price per share without interest, less any applicable withholding taxes.</p><p>In addition, upon completion of the merger, Cubist will become a wholly owned subsidiary of Merck and the common stock of Cubist will cease to be traded on the NASDAQ Stock Market.</p><p><p><img src="image/20201019/5010bad2874b9a451c33b6642a14d0a7_1.jpg" /></p></p><p><legend><span><strong><span>冠维医修</span></strong><strong><span>ID: </span></strong></span></legend></p><p><legend><span><strong><span></span></strong></span></legend></p><p><span><span>华康冠维（北京）医疗器械维修有限公司倾力打造的集医疗设备管理、全院系维修、工程师培训、加盟连锁于一体的行业标杆性品牌企业。经过8年的摸索和市场历练，由单一的医疗设备维修第三方医疗服务公司成长为今天以医疗设备质量管理为核心、包含信息化管理、全院</span></span><span>设备检测与快修为支撑的现代化医疗设备综合管理服务公司品牌。</span></p><p><span><span>400 - 666 - 8263</span></span></p><p><span><span><br /></span></span></p><p><br /></p>
|
|
发表于 2020-10-19 15:39:26